anti-Bevacizumab ELISA试剂盒(ab237658)
Key features and details
- Sensitivity: 30 ng/ml
- Range: 62 ng/ml - 500 ng/ml
- Sample type: Plasma, Serum
- Detection method: Colorimetric
- Assay type: Sandwich (quantitative)
- Reacts with: Human
概述
-
产品名称
anti-Bevacizumab ELISA试剂盒
参阅全部 Bevacizumab 试剂盒 -
检测方法
Colorimetric -
精确度
批次内 样品 n Mean SD CV% Overall < 15% 批次间 样品 n Mean SD CV% Overall < 15% -
样品类型
Serum, Plasma -
检测类型
Sandwich (quantitative) -
灵敏度
30 ng/ml -
范围
62 ng/ml - 500 ng/ml -
回收率
特定样本回收率 样品类型 平均% 范围 Serum 85% - 115% -
实验步骤
Multiple steps standard assay -
种属反应性
与反应: Human -
产品概述
anti-Bevacizumab ELISA Kit (ab237658) is designed to quantify/measure the antibody against Bevacizumab with high specificity and sensitivity in biological matrices.
-
说明
This product is manufactured by BioVision, an Abcam company and was previously called E4389 BioSim™ anti-Bevacizumab (Human) ELISA Kit. E4389-100 is the same size as the 96 test size of ab237658.
-
平台
Microplate
性能
-
存放说明
Store at +4°C. Please refer to protocols. -
组件 96 tests Micro ELISA Plate 1 unit Bevacizumab standard 1 1 x 1ml Bevacizumab standard 2 1 x 1ml Bevacizumab Standard 3 1 x 1ml Bevacizumab Standard 4 1 x 1ml Bevacizumab Standard 5 1 x 1ml Bevacizumab Standard 6 1 x 1ml Bevacizumab Standard 7 1 x 1ml Assay Buffer 1 x 50ml Confirmation Reagent 1 x 12ml Peroxidase Conjugate 1 x 12ml TMB substrate 1 x 12ml Stop Solution 1 x 12ml Wash buffer (20X) 1 x 50ml Plate sealers 2 tablets -
相关性
Bevacizumab is a recombinant human IgG1 monoclonal antibody specific for all human vascular endothelial growth factor-A (VEGF-A) isoforms. The humanized anti-VEGF monoclonal antibody, bevacizumab, has been approved by the FDA as a first-line treatment for metastatic colorectal cancer in combination with chemotherapy. The pharmacokinetic properties of bevacizumab in several species have been previously described and are consistent with a typical humanized monoclonal antibody. It was shown in the literature that the surveillance of circulating concentration during maintenance therapy represents a direct and/or indirect factor for some other side effects. Identification of biomarkers for (non-)response and risk factors for adverse drug reactions that might be related to serum concentrations and maintaining the effective concentration of Bevacizumab in order to potentially avoid some side effects with a reliable method might be beneficial.
图片
数据表及文件
-
SDS download
-
Datasheet download
文献 (0)
ab237658 尚未被引用在任何文献中。